|Bid||33.10 x 1100|
|Ask||0.00 x 2200|
|Day's Range||56.23 - 60.78|
|52 Week Range||37.44 - 90.98|
|Beta (3Y Monthly)||2.88|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 18, 2019 - Feb 22, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||72.39|
DTX401 Response in Time to Hypoglycemia and Improved Glucose Control Maintained or Improved in All Three Patients Data from Higher-dose Cohort 2 Expected Mid-2019 NOVATO,.
NEW YORK, Feb. 21, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Ultragenyx Pharmaceutical stock jumped to a four-month high Wednesday on its strong launch for Crysvita, which treats a form of rickets. The firm is also working on other rare-disease drugs.
The Novato, California-based company said it had a loss of $1.73 per share. The results exceeded Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was ...
NOVATO, Calif., Feb. 19, 2019 -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and.
NEW YORK, NY / ACCESSWIRE / February 19, 2019 / Ultragenyx Pharmaceutical, Inc. (NASDAQ: RARE ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 19, ...
Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, Kyowa Hakko Kirin Co. Ltd (Kyowa Hakko Kirin), and Kyowa Kirin International PLC (Kyowa Kirin International) today announced positive results of a 64-week efficacy and safety analysis of the randomized active-controlled Phase 3 study of Crysvita® (burosumab) in children with X-linked hypophosphatemia (XLH) compared with oral phosphate and active vitamin D (current conventional therapy). The new results showed that Crysvita was superior to conventional therapy for all key efficacy endpoints, showing a meaningful improvement in rickets severity, lower limb deformity, growth, and physical functioning as demonstrated by increases in distance walked.
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Tuesday, February 19, 2019 at 5pm ET to discuss its financial results and corporate update for the fourth quarter and the year ended December 31, 2018. Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are no approved therapies.
Ultragenyx Pharmaceutical Inc NASDAQ/NGS:RAREView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for RARE with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding RARE totaled $2.21 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Stocks with market capitalization between $2B and Read More...
Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced the appointment of Shehnaaz Suliman, M.D., to the company’s Board of Directors, effective January 30, 2019. Dr. Suliman, Senior Vice President of Corporate Development and Strategy of Theravance Biopharma, Inc., will serve as an independent director to Ultragenyx. “Dr. Suliman joins the Ultragenyx Board at a key time for the company, and her corporate and commercial strategy experience will be a valuable asset as we continue to advance our pipeline and deliver therapies to patients with rare diseases in need of treatment options,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx.
Shares of Ultragenyx Pharmaceutical Inc. rose 2.9% in premarket trade Tuesday after the company announced positive results from a safety and efficacy study looking at a treatment for patients with long-chain fatty acid oxidation disorder. Patients with this disorder are unable to properly break down fatty acids into energy, leading to serious liver, muscle and heart issues. Researchers looked at how Ultragenyx's drug, UX007, affected 75 patients, including 29 from a previous UX007 Phase 2 trial showing that UX007-treated patients had fewer illness-related visits to the hospital and fewer days in the hospital per year. The safety and efficacy study reaffirmed those results, also showing a reduction in the median number of hospital visits and days in the hospital per year among those treated with the drug. Ultragenyx said it is still on track to submit a new drug application for UX007 in mid-2019. Shares of Ultragenyx have gained 22.7% in the year to date through Friday, while the iShares Nasdaq Biotechnology ETF has gained 14.6%. The S&P 500 has gained 6.5%.
Reductions in Major Clinical Events SustainedAfter an Additional 78 Weeks of UX007 Treatment Additional 20 Patients Naïve to UX007 Also Demonstrated Meaningful Reductions.
NEW YORK, Jan. 11, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
NEW YORK, NY / ACCESSWIRE / January 11, 2019 / U.S. markets finished in the green on Thursday, however gains were held back by a sharp decline in Macy’s shares that pressured retail stocks lower. The Dow ...
As corporate diversity issues are in the spotlight, a small group will assemble at the J.P. Morgan Healthcare Conference to build a network of current and potential LGBTQ board members.
From spotting buzz-words to scouting out prospective employers, here's our field guide for the 37th annual J.P. Morgan Healthcare Conference and the other events that collectively form JPM Week.